



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/873059/2018

European Medicines Agency decision P/0005/2019

of 3 January 2019

on the granting of a product specific waiver for palbociclib (IBRANCE) (EMEA-002146-PIP02-18) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.



European Medicines Agency decision

P/0005/2019

of 3 January 2019

on the granting of a product specific waiver for palbociclib (IBRANCE) (EMA-002146-PIP02-18) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Pfizer Europe MA EEIG on 6 August 2018 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 16 November 2018 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

Has adopted this decision:

Article 1

A waiver for palbociclib (IBRANCE), capsule, hard, tablet, age-appropriate oral dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 – Brussels, Belgium.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/607466/2018
London, 16 November 2018

Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-002146-PIP02-18

Scope of the application

Active substance(s):

Palbociclib

Invented name:

IBRANCE

Condition(s):

Treatment of breast malignant neoplasms

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Capsule, hard

Tablet

Age-appropriate oral dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Pfizer Europe MA EEIG

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Pfizer Europe MA EEIG submitted to the European Medicines Agency on 6 August 2018 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 18 September 2018.

Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition:

Treatment of breast malignant neoplasms

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- capsule, hard, tablet, age-appropriate oral dosage form, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of breast malignant neoplasms

Authorised indication(s):

IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer:

- in combination with an aromatase inhibitor;
- in combination with fulvestrant in women who have received prior endocrine therapy.

In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.

Authorised pharmaceutical form(s):

Capsule, hard

Authorised route(s) of administration:

Oral use